Journal Article
. 2004 Oct; 15(8):753-60.
doi: 10.1097/00001813-200409000-00003.

Acute effects of tamoxifen and third-generation aromatase inhibitors on menopausal symptoms of breast cancer patients

Leilani Morales 1 Patrick Neven  Dirk Timmerman  Marie-Rose Christiaens  Ignace Vergote  Erik Van Limbergen  An Carbonez  Sabine Van Huffel  Lieveke Ameye  Robert Paridaens  
Affiliations
  • PMID: 15494636
  •     32 citations

Abstract

Endocrine treatments of breast cancer patients antagonize estrogen and may lead to consequences of estrogen deprivation including menopausal symptoms. We analyzed the changes in frequency and severity of menopausal symptoms in patients receiving tamoxifen or aromatase inhibitors and identified factors influencing these symptoms. One hundred and eighty-one consecutive postmenopausal breast cancer patients scheduled to start endocrine treatment were included in this prospective study. A menopause symptom questionnaire covering vasomotor, atrophic, psychological, cognitive and somatic symptoms was filled in at baseline, and after 1 and 3 months of therapy. Both first-line tamoxifen and aromatase inhibitors induced an increase in the occurrence and severity of hot flashes (p<0.0001 and p=0.014, respectively). Musculoskeletal pain and dyspareunia significantly increased under first-line non-steroidal aromatase inhibitors (p=0.0039 and p=0.001, respectively), while patients under tamoxifen had significant decrease in sexual interest (p< or =0.0001). Younger age was associated with more hot flashes and vaginal dryness at baseline, and after 1 and 3 months of therapy (all p<0.02). We conclude that there are significant differences between the early effects of tamoxifen and aromatase inhibitors on menopausal symptoms of breast cancer patients. Our results underscore the need for safe and effective non-hormonal interventions to alleviate vasomotor and musculoskeletal symptoms which were the most prevalent and severe symptoms.

Effects of tamoxifen on vaginal blood flow and epithelial morphology in the rat.
Noel N Kim, Miljan Stankovic, +3 authors, Abdulmaged M Traish.
BMC Womens Health, 2006 Sep 15; 6. PMID: 16970814    Free PMC article.
Differential effects of tamoxifen and anastrozole on optic cup size in breast cancer survivors.
Alvin Eisner, Maureen D Toomey, +2 authors, John T Vetto.
Breast Cancer Res Treat, 2007 Jan 30; 106(2). PMID: 17260092    Free PMC article.
Should menopausal women at increased risk for breast cancer use tamoxifen, raloxifene, or hormone therapy?: a framework for personalized risk assessment and counseling.
Ellen T Matloff, Kristen M Shannon, Anne Moyer, Nananda F Col.
J Cancer Educ, 2007 Jun 16; 22(1). PMID: 17570802
The what, why and how of aromatase inhibitors: hormonal agents for treatment and prevention of breast cancer.
C J Fabian.
Int J Clin Pract, 2007 Sep 26; 61(12). PMID: 17892469    Free PMC article.
Review.
Safety of aromatase inhibitors in the adjuvant setting.
Edith A Perez.
Breast Cancer Res Treat, 2007 Nov 21; 105 Suppl 1. PMID: 17912638    Free PMC article.
Review.
Yoga of Awareness program for menopausal symptoms in breast cancer survivors: results from a randomized trial.
James W Carson, Kimberly M Carson, +2 authors, Victoria L Seewaldt.
Support Care Cancer, 2009 Feb 14; 17(10). PMID: 19214594
Effect of vitamin D supplementation on serum 25-hydroxy vitamin D levels, joint pain, and fatigue in women starting adjuvant letrozole treatment for breast cancer.
Qamar J Khan, Pavan S Reddy, +5 authors, Carol J Fabian.
Breast Cancer Res Treat, 2009 Aug 06; 119(1). PMID: 19655244    Free PMC article.
Amelioration of sexual adverse effects in the early breast cancer patient.
Michelle E Melisko, Mindy Goldman, Hope S Rugo.
J Cancer Surviv, 2010 Jul 06; 4(3). PMID: 20602189    Free PMC article.
Review.
High prevalence of low vitamin D and musculoskeletal complaints in women with breast cancer.
Nicola Napoli, Swapna Vattikuti, +7 authors, Reina Armamento-Villareal.
Breast J, 2010 Nov 13; 16(6). PMID: 21070438    Free PMC article.
Topical testosterone for breast cancer patients with vaginal atrophy related to aromatase inhibitors: a phase I/II study.
Sabrina Witherby, Julia Johnson, +5 authors, Hyman Muss.
Oncologist, 2011 Mar 10; 16(4). PMID: 21385795    Free PMC article.
Urinary symptoms in breast cancer: a systematic review.
Kristine A Donovan, Alice R Boyington, Roohi Ismail-Khan, Jean F Wyman.
Cancer, 2011 Jul 14; 118(3). PMID: 21751193    Free PMC article.
Systematic Review.
Update on alternative therapies for vulvovaginal atrophy.
Janet A Chollet.
Patient Prefer Adherence, 2011 Nov 25; 5. PMID: 22114467    Free PMC article.
Quality of life in relation to tamoxifen or exemestane treatment in postmenopausal breast cancer patients: a Tamoxifen Exemestane Adjuvant Multinational (TEAM) Trial side study.
J G H van Nes, D B Y Fontein, +7 authors, C J H van de Velde.
Breast Cancer Res Treat, 2012 Mar 29; 134(1). PMID: 22453754    Free PMC article.
Risk factors, pathophysiology, and treatment of hot flashes in cancer.
William I Fisher, Aimee K Johnson, +4 authors, Janet S Carpenter.
CA Cancer J Clin, 2013 Jan 29; 63(3). PMID: 23355109    Free PMC article.
Review.
Patient-reported outcomes in women with breast cancer enrolled in a dual-center, double-blind, randomized controlled trial assessing the effect of acupuncture in reducing aromatase inhibitor-induced musculoskeletal symptoms.
Ting Bao, Ling Cai, +11 authors, Vered Stearns.
Cancer, 2014 Jan 01; 120(3). PMID: 24375332    Free PMC article.
Sexual problems during the first 2 years of adjuvant treatment with aromatase inhibitors.
Leslie R Schover, George P Baum, +2 authors, Amal Melhem-Bertrandt.
J Sex Med, 2014 Aug 22; 11(12). PMID: 25141792    Free PMC article.
Course and Moderators of Hot Flash Interference during Androgen Deprivation Therapy for Prostate Cancer: A Matched Comparison.
Brian D Gonzalez, Heather S L Jim, +7 authors, Paul B Jacobsen.
J Urol, 2015 Mar 21; 194(3). PMID: 25791402    Free PMC article.
Atrophic vaginitis in breast cancer survivors: a difficult survivorship issue.
Joanne Lester, Gaurav Pahouja, Barbara Andersen, Maryam Lustberg.
J Pers Med, 2015 Mar 31; 5(2). PMID: 25815692    Free PMC article.
Sensitization of estrogen receptor-positive breast cancer cell lines to 4-hydroxytamoxifen by isothiocyanates present in cruciferous plants.
Anna Pawlik, Monika Słomińska-Wojewódzka, Anna Herman-Antosiewicz.
Eur J Nutr, 2015 May 28; 55(3). PMID: 26014809    Free PMC article.
Impact of Adjuvant Endocrine Therapy on Quality of Life and Symptoms: Observational Data Over 12 Months From the Mind-Body Study.
Patricia A Ganz, Laura Petersen, Julienne E Bower, Catherine M Crespi.
J Clin Oncol, 2016 Jan 21; 34(8). PMID: 26786934    Free PMC article.
Breast cancer and sexual function.
Erica N Boswell, Don S Dizon.
Transl Androl Urol, 2016 Jan 28; 4(2). PMID: 26816822    Free PMC article.
Review.
Hot flashes in breast cancer survivors: Frequency, severity and impact.
Hao-Yuan Chang, Aparna C Jotwani, +4 authors, Julie Gralow.
Breast, 2016 Apr 12; 27. PMID: 27065357    Free PMC article.
Factors related to the experience of menopausal symptoms in women prescribed tamoxifen.
Zoe Moon, Myra S Hunter, Rona Moss-Morris, Lyndsay Dawn Hughes.
J Psychosom Obstet Gynaecol, 2016 Sep 02; 38(3). PMID: 27583832    Free PMC article.
Endocrine therapy and urogenital outcomes among women with a breast cancer diagnosis.
Suzanne N Landi, Kemi M Doll, +4 authors, Hazel B Nichols.
Cancer Causes Control, 2016 Sep 30; 27(11). PMID: 27680018    Free PMC article.
BreastDefend enhances effect of tamoxifen in estrogen receptor-positive human breast cancer in vitro and in vivo.
Shujie Cheng, Victor Castillo, +5 authors, Daniel Sliva.
BMC Complement Altern Med, 2017 Feb 18; 17(1). PMID: 28209156    Free PMC article.
Efficacy of a biobehavioral intervention for hot flashes: a randomized controlled pilot study.
Debra L Barton, Kelliann C Fee Schroeder, +3 authors, Gary Elkins.
Menopause, 2017 Mar 08; 24(7). PMID: 28266949    Free PMC article.
Investigating Associations Between Health-Related Quality of Life and Endocrine Therapy Underuse in Women With Early-Stage Breast Cancer.
Laura C Pinheiro, Stephanie B Wheeler, +3 authors, Bryce B Reeve.
J Oncol Pract, 2017 Mar 16; 13(5). PMID: 28291383    Free PMC article.
Effects of tamoxifen on urinary incontinence: Case report and review of literature.
Elshad Hasanov, Merve Hasanov, +4 authors, Kadri Altundag.
Medicine (Baltimore), 2017 Aug 24; 96(34). PMID: 28834864    Free PMC article.
Prognostic value of PAM50 and risk of recurrence score in patients with early-stage breast cancer with long-term follow-up.
Hege O Ohnstad, Elin Borgen, +11 authors, Bjørn Naume.
Breast Cancer Res, 2017 Nov 16; 19(1). PMID: 29137653    Free PMC article.
Adherence to endocrine therapy among Chinese patients with breast cancer: current status and recommendations for improvement.
Pin Gao, Lili You, +9 authors, Zhimin Fan.
Patient Prefer Adherence, 2018 Jun 07; 12. PMID: 29872274    Free PMC article.
Prevalence and risk factors of sleep disturbances in breast cancersurvivors: systematic review and meta-analyses.
Laurence Leysen, Astrid Lahousse, +7 authors, David Beckwée.
Support Care Cancer, 2019 Jul 28; 27(12). PMID: 31346744
Systematic Review.
Topical treatment of vaginal dryness with a non-hormonal cream in women undergoing breast cancer treatment - An open prospective multicenter study.
Dimitrios Chatsiproios, Iris M Schmidts-Winkler, +2 authors, Christoph Abels.
PLoS One, 2019 Jan 25; 14(1). PMID: 30677065    Free PMC article.